전이성 골질환 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 9.8%의 CAGR로 274억 9,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 노인 인구 증가, 새로운 방사성의약품 개발에 대한 관심 증가, 급여 정책, 첨단 치료법 개발, 효과적인 통증 관리 치료에 대한 수요 증가, 전이성 뼈 질환에 대한 인식 증가 등에 기인하는 것으로 분석됩니다. 예측 기간 동안 주요 동향으로는 진단 기술 개발, 진단 기술 향상, 치료 접근법의 신규성, 인공지능 및 기계 학습 알고리즘, 뼈 건강 관리 기술 개발 등을 꼽을 수 있습니다.
골암의 유병률 증가는 전이성 뼈 질환 시장의 성장을 촉진할 것으로 예상됩니다. 뼈 세포에서 발생하는 악성 종양인 골암은 유전적 요인, 방사선 노출, 특정 화학제품에 대한 노출과 같은 환경적 요인에 의해 발생합니다. 골암은 원발 종양의 암세포가 혈류와 림프계를 통해 퍼져 다른 뼈에 새로운 종양을 형성하기 때문에 전이성 골질환으로 이어질 수 있습니다. 예를 들어, 미국에 본사를 둔 비영리 단체인 미국 암 협회는 2023년에 3,970건의 새로운 뼈 및 관절암 사례를 보고했는데, 이는 2022년에 보고된 3,910건보다 증가한 수치입니다. 따라서 골암의 유병률 증가가 전이성 뼈 질환 시장의 성장을 주도하고 있습니다.
전이성 골질환 시장의 주요 기업들은 치료 결과를 개선하기 위해 표적 치료제를 개발하고 있습니다. 이러한 표적 치료제는 암세포를 정확하게 표적화하고, 건강한 세포의 손상을 최소화하며, 환자 개개인의 분자적 특성에 기반한 개별화된 치료 접근법을 제공함으로써 전이성 골질환에 기여하고 있습니다. 예를 들어, 스위스에 본사를 둔 제약회사 노바티스(Novartis AG)는 지난 3월 고형암 및 다발성 골수종 골전이 환자의 골격 관련 사건 예방에 대한 적응증으로 비스포스포네이트 계열의 조메타(Zometa, 성분명: 졸레드론산)를 승인받았습니다. 이러한 발전은 전이성 골질환 환자의 치료 결과와 삶의 질을 개선하는 것을 목표로 하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신종 코로나바이러스 감염증, 그리고 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 전이성 골질환 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 전이성 골질환 시장 : 성장률 분석
- 세계의 전이성 골질환 시장 실적 : 규모와 성장, 2019-2024
- 세계의 전이성 골질환 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 전이성 골질환 전체 시장(TAM)
제6장 시장 세분화
- 세계의 전이성 골질환 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 약
- 방사선 치료
- 외과적 개입
- 종양 절제 요법
- 세계의 전이성 골질환 시장 : 기원별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 흉
- 폐
- 갑상선
- 신장
- 전립선
- 기타 기원
- 세계의 전이성 골질환 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 전문 클리닉
- 외래 수술 센터
- 세계의 전이성 골질환 시장, 의약품 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 비스포스포네이트
- 데노스마브
- 화학요법제
- 호르몬요법
- 표적요법
- 방사선 치료
- 세계의 전이성 골질환 시장, 방사선 치료 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 외부 방사선 치료
- 내부 방사선 치료
- 세계의 전이성 골질환 시장, 외과적 개입 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 뼈안정화 수술
- 뼈절제 수술
- 척추 감압 수술
- 세계의 전이성 골질환 시장, 종양 절제 요법 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 고주파 절제
- 냉동요법
- 마이크로파 절제
제7장 지역별·국가별 분석
- 세계의 전이성 골질환 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 전이성 골질환 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 전이성 골질환 시장 : 경쟁 구도
- 전이성 골질환 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bayer AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- Sanofi SA
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Novartis AG
- GSK plc
- Takeda Pharmaceutical Company Limited
- Medtronic plc
- Eli Lilly and Company
- Amgen Inc.
- Boston Scientific Corporation
- Regeneron Pharmaceuticals Inc.
- Astellas Pharma Inc.
- Daiichi Sankyo Company Limited
- Jazz Pharmaceuticals Inc.
- Exelixis Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 전이성 골질환 시장 2029 : 새로운 기회를 제공하는 국가
- 전이성 골질환 시장 2029 : 새로운 기회를 제공하는 부문
- 전이성 골질환 시장 2029 : 성장 전략
제36장 부록
ksm
Metastatic bone disease refers to the condition where cancer cells spread from their original (primary) site to the bones, causing bone weakening and symptoms such as pain, fractures, spinal cord compression, and hypercalcemia. This indicates that the cancer has progressed and is more challenging to treat.
The main treatments for metastatic bone disease include medication, radiation therapy, surgical intervention, and tumor ablation therapy. Medication involves pharmaceutical drugs used to manage symptoms, slow disease progression, or address the underlying causes of bone metastases. These treatments are applicable to cancers originating from the breast, lung, thyroid, kidney, prostate, and other sites. The various end-users of these treatments include hospitals, specialty clinics, and ambulatory surgical centers.
The metastatic bone disease market research report is one of a series of new reports from The Business Research Company that provides metastatic bone disease market statistics, including the metastatic bone disease industry global market size, regional shares, competitors with metastatic bone disease market share, detailed metastatic bone disease market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic bone disease industry. These metastatic bone disease market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The metastatic bone disease market size has grown rapidly in recent years. It will grow from $17.14 billion in 2024 to $18.88 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to an increased aging population, increased cancer awareness programs, growth in the demand for effective pain management therapies, high investment in drug discovery and development, and adoption of unhealthy lifestyles.
The metastatic bone disease market size is expected to see strong growth in the next few years. It will grow to $27.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to the increasing geriatric population, increasing focus on developing novel radiopharmaceutical drugs, reimbursement policies, creation of cutting-edge treatment, growing demand for effective pain management therapies, and rising awareness about metastatic bone disease. Major trends in the forecast period include technological developments in diagnostics, improved diagnostic techniques, novelties in therapeutic approaches, artificial intelligence and machine learning algorithms, and technological developments in the management of bone health.
The increasing prevalence of bone cancer is expected to propel the growth of the metastatic bone disease market. Bone cancer, a malignant tumor originating in the cells of the bone, is driven by genetic factors, radiation exposure, and environmental factors such as exposure to certain chemicals. Bone cancer can lead to metastatic bone disease as cancer cells from the primary tumor spread through the bloodstream or lymphatic system, forming new tumors in other bones. For instance, in 2023, the American Cancer Society, a US-based non-profit organization, reported 3,970 new cases of bone and joint cancer, an increase from the 3,910 cases reported in 2022. Therefore, the increasing prevalence of bone cancer is driving the growth of the metastatic bone disease market.
Major companies in the metastatic bone disease market are developing targeted therapies to improve treatment outcomes. These targeted therapies help in metastatic bone disease by precisely targeting cancer cells, minimizing damage to healthy cells, and offering a personalized treatment approach based on the individual patient's molecular characteristics. For example, in March 2022, Novartis AG, a Switzerland-based pharmaceutical company, introduced Zometa (zoledronic acid), a bisphosphonate medication approved for the prevention of skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma. These advancements aim to improve treatment outcomes and quality of life for patients with metastatic bone disease.
In May 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, acquired QSAM Biosciences for an undisclosed amount. This acquisition aims to bolster Telix's therapeutic pipeline, strengthening its position in radiopharmaceutical innovation and widening its focus on oncology and rare diseases. Through this deal, Telix intends to accelerate the development and delivery of treatments for bone metastases, aiming to provide significant benefits to affected patients. QSAM Biosciences Inc. is a US-based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.
Major companies operating in the metastatic bone disease market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Eli Lilly and Company, Amgen Inc., Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Jazz Pharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Mylan N.V., Novocure GmbH, Galapagos NV, Telix Pharmaceuticals Limited
North America was the largest region in the metastatic bone disease market in 2024. The regions covered in the metastatic bone disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the metastatic bone disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The metastatic bone disease market consists of revenues earned by entities by providing services such as chemotherapy, hormone therapy, bisphosphonates, opiate therapy, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic bone disease market includes sales of intramedullary rods, plates and screws, prosthetic devices, spinal instrumentation, and radiation therapy accessories. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Metastatic Bone Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on metastatic bone disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for metastatic bone disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metastatic bone disease market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment: Medication; Radiation Therapy; Surgical Intervention; Tumor Ablation Therapy
- 2) By Origin: Breast; Lung; Thyroid; Kidney; Prostate; Other Origins
- 3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers
- Subsegments:
- 1) By Medication: Bisphosphonates; Denosumab; Chemotherapy Drugs; Hormonal Therapies; Targeted Therapies; Radiation Therapy
- 2) By Radiation Therapy: External Beam Radiation Therapy; Internal Radiation Therapy
- 3) By Surgical Intervention: Bone Stabilization Surgery; Bone Resection Surgery; Spinal Decompression Surgery
- 4) By Tumor Ablation Therapy: Radiofrequency Ablation; Cryoablation; Microwave Ablation
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; Bayer AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Metastatic Bone Disease Market Characteristics
3. Metastatic Bone Disease Market Trends And Strategies
4. Metastatic Bone Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Metastatic Bone Disease Growth Analysis And Strategic Analysis Framework
- 5.1. Global Metastatic Bone Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Metastatic Bone Disease Market Growth Rate Analysis
- 5.4. Global Metastatic Bone Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Metastatic Bone Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Metastatic Bone Disease Total Addressable Market (TAM)
6. Metastatic Bone Disease Market Segmentation
- 6.1. Global Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Medication
- Radiation Therapy
- Surgical Intervention
- Tumor Ablation Therapy
- 6.2. Global Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Breast
- Lung
- Thyroid
- Kidney
- Prostate
- Other Origins
- 6.3. Global Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- 6.4. Global Metastatic Bone Disease Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Bisphosphonates
- Denosumab
- Chemotherapy Drugs
- Hormonal Therapies
- Targeted Therapies
- Radiation Therapy
- 6.5. Global Metastatic Bone Disease Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- External Beam Radiation Therapy
- Internal Radiation Therapy
- 6.6. Global Metastatic Bone Disease Market, Sub-Segmentation Of Surgical Intervention, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Bone Stabilization Surgery
- Bone Resection Surgery
- Spinal Decompression Surgery
- 6.7. Global Metastatic Bone Disease Market, Sub-Segmentation Of Tumor Ablation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Radiofrequency Ablation
- Cryoablation
- Microwave Ablation
7. Metastatic Bone Disease Market Regional And Country Analysis
- 7.1. Global Metastatic Bone Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Metastatic Bone Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Metastatic Bone Disease Market
- 8.1. Asia-Pacific Metastatic Bone Disease Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Metastatic Bone Disease Market
- 9.1. China Metastatic Bone Disease Market Overview
- 9.2. China Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Metastatic Bone Disease Market
- 10.1. India Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Metastatic Bone Disease Market
- 11.1. Japan Metastatic Bone Disease Market Overview
- 11.2. Japan Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Metastatic Bone Disease Market
- 12.1. Australia Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Metastatic Bone Disease Market
- 13.1. Indonesia Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Metastatic Bone Disease Market
- 14.1. South Korea Metastatic Bone Disease Market Overview
- 14.2. South Korea Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Metastatic Bone Disease Market
- 15.1. Western Europe Metastatic Bone Disease Market Overview
- 15.2. Western Europe Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Metastatic Bone Disease Market
- 16.1. UK Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Metastatic Bone Disease Market
- 17.1. Germany Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Metastatic Bone Disease Market
- 18.1. France Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Metastatic Bone Disease Market
- 19.1. Italy Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Metastatic Bone Disease Market
- 20.1. Spain Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Metastatic Bone Disease Market
- 21.1. Eastern Europe Metastatic Bone Disease Market Overview
- 21.2. Eastern Europe Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Metastatic Bone Disease Market
- 22.1. Russia Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Metastatic Bone Disease Market
- 23.1. North America Metastatic Bone Disease Market Overview
- 23.2. North America Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Metastatic Bone Disease Market
- 24.1. USA Metastatic Bone Disease Market Overview
- 24.2. USA Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Metastatic Bone Disease Market
- 25.1. Canada Metastatic Bone Disease Market Overview
- 25.2. Canada Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Metastatic Bone Disease Market
- 26.1. South America Metastatic Bone Disease Market Overview
- 26.2. South America Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Metastatic Bone Disease Market
- 27.1. Brazil Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Metastatic Bone Disease Market
- 28.1. Middle East Metastatic Bone Disease Market Overview
- 28.2. Middle East Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Metastatic Bone Disease Market
- 29.1. Africa Metastatic Bone Disease Market Overview
- 29.2. Africa Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Metastatic Bone Disease Market Competitive Landscape And Company Profiles
- 30.1. Metastatic Bone Disease Market Competitive Landscape
- 30.2. Metastatic Bone Disease Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Metastatic Bone Disease Market Other Major And Innovative Companies
- 31.1. Sanofi SA
- 31.2. Bristol-Myers Squibb Company
- 31.3. AstraZeneca plc
- 31.4. Novartis AG
- 31.5. GSK plc
- 31.6. Takeda Pharmaceutical Company Limited
- 31.7. Medtronic plc
- 31.8. Eli Lilly and Company
- 31.9. Amgen Inc.
- 31.10. Boston Scientific Corporation
- 31.11. Regeneron Pharmaceuticals Inc.
- 31.12. Astellas Pharma Inc.
- 31.13. Daiichi Sankyo Company Limited
- 31.14. Jazz Pharmaceuticals Inc.
- 31.15. Exelixis Inc.
32. Global Metastatic Bone Disease Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Metastatic Bone Disease Market
34. Recent Developments In The Metastatic Bone Disease Market
35. Metastatic Bone Disease Market High Potential Countries, Segments and Strategies
- 35.1 Metastatic Bone Disease Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Metastatic Bone Disease Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Metastatic Bone Disease Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
